-
公开(公告)号：US08501185B2
公开(公告)日：2013-08-06
申请号：US12302283
申请日：2007-05-24
Applicant: Tara Renee Heitner Hansen , David Light , Kirk McLean , Renate Parry , Noboru Satozawa , Douglas Schneider , Marian Seto
Inventor： Tara Renee Heitner Hansen , David Light , Kirk McLean , Renate Parry , Noboru Satozawa , Douglas Schneider , Marian Seto
CPC classification number: C07K16/00 , C07K16/3069 , C07K2317/52 , C07K2317/53 , C07K2317/55 , C07K2317/622 , C07K2319/30
Abstract: Dimeric molecular complexes useful for diagnostics and therapeutics.
Abstract translation: 用于诊断和治疗的二聚体分子复合物。
-
公开(公告)号：US20120178693A1
公开(公告)日：2012-07-12
申请号：US13393157
申请日：2010-08-28
Applicant: David Light , Maxine Bauzon , David Kiewlich , Terry Hermiston
Inventor： David Light , Maxine Bauzon , David Kiewlich , Terry Hermiston
CPC classification number: C07K14/745 , A61K38/00
Abstract: The invention relates to fusion proteins that bind the enzyme thrombin and enhance the activation of the substrate Factor VII to the product Factor VIIa. The invention is also directed to polynucleotides, vectors, host cells, pharmaceutical compositions, and methods of treatment.
Abstract translation: 本发明涉及结合酶凝血酶并增强底物因子VII对产物因子VIIa的活化的融合蛋白。 本发明还涉及多核苷酸，载体，宿主细胞，药物组合物和治疗方法。
-
公开(公告)号：US20110229476A1
公开(公告)日：2011-09-22
申请号：US12671942
申请日：2008-08-16
Applicant: Bing Liu , David Light , Zhuozhi Wang , Douglas Schneider
Inventor： Bing Liu , David Light , Zhuozhi Wang , Douglas Schneider
IPC: A61K39/395 , C07K16/44 , G01N33/53 , C12N9/96 , A61P35/00 , A61P35/02 , A61P29/00 , A61P3/10 , A61P25/00 , A61P19/02 , A61P7/06 , A61P17/06 , A61P1/12 , A61P33/06 , A61P31/04 , A61P31/00 , A61P31/18 , A61P31/06 , A61P31/14 , A61P31/20
CPC classification number: C07K16/468 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6803 , A61K47/6807 , A61K47/6809 , A61K47/6821 , A61K47/6827 , A61K47/6829 , A61K47/6851 , A61K47/6869 , A61K2039/505 , C07K16/3069 , C07K16/3076 , C07K16/36 , C07K2317/31 , C07K2317/56 , C07K2317/64 , Y02A50/412
Abstract: This invention relates to monospecific and multispecific antibodies that may be utilized for the diagnosis and treatment of various diseases. In addition, these antibodies may be modified by protease cleavage. Protease control or regulation may be provided by a protease site located in, for example, a linker. These protease-regulated antibodies may also be utilized for the diagnosis and treatment of various diseases.
Abstract translation: 本发明涉及可用于诊断和治疗各种疾病的单特异性和多特异性抗体。 此外，这些抗体可以通过蛋白酶切割来修饰。 蛋白酶控制或调节可以由位于例如接头的蛋白酶位点提供。 这些蛋白酶调节的抗体也可用于各种疾病的诊断和治疗。
-
公开(公告)号：US20110201523A1
公开(公告)日：2011-08-18
申请号：US13027336
申请日：2011-02-15
Applicant: Wolfgang HINZ , John Leamon , David Light , Jonathan Rothberg
Inventor： Wolfgang HINZ , John Leamon , David Light , Jonathan Rothberg
IPC: C40B40/06
CPC classification number: C12N15/1093 , B01J19/0046 , B01J2219/00466 , B01J2219/005 , B01J2219/00596 , B01J2219/00722 , C12Q1/6874 , C40B40/08 , C40B50/06 , Y10T428/2982
Abstract: The invention provides particle compositions having applications in nucleic acid analysis. Nucleic acid polymer particles of the invention allow polynucleotides to be attached throughout their volumes for higher loading capacities than those achievable solely with surface attachment. In one aspect, nucleic acid polymer particles of the invention comprise polyacrylamide particles with uniform size distributions having low coefficients of variations, which result in reduced particle-to-particle variation in analytical assays. Such particle compositions are used in various amplification reactions to make amplicon libraries from nucleic acid fragment libraries.
Abstract translation: 本发明提供了在核酸分析中具有应用的颗粒组合物。 本发明的核酸聚合物颗粒允许多核苷酸在其整个体积中被连接，以便比仅通过表面附着可实现的更高的负载能力。 在一个方面，本发明的核酸聚合物颗粒包含具有低变异系数的具有均匀尺寸分布的聚丙烯酰胺颗粒，这导致分析测定中颗粒对颗粒的变化减少。 这种颗粒组合物用于各种扩增反应以制备来自核酸片段文库的扩增子文库。
-
35.发明申请公开(公告)号：US20110195252A1
公开(公告)日：2011-08-11
申请号：US13026707
申请日：2011-02-14
Applicant: Wolfgang HINZ , John Leamon , David Light , Jonathan Rothberg
Inventor： Wolfgang HINZ , John Leamon , David Light , Jonathan Rothberg
IPC: B32B5/00 , C08F265/10
CPC classification number: C12N15/1093 , B01J19/0046 , B01J2219/00466 , B01J2219/005 , B01J2219/00596 , B01J2219/00722 , C12Q1/6874 , C40B40/08 , C40B50/06 , Y10T428/2982
Abstract: The invention provides particle compositions having applications in nucleic acid analysis. Nucleic acid polymer particles of the invention allow polynucleotides to be attached throughout their volumes for higher loading capacities than those achievable solely with surface attachment. In one aspect, nucleic acid polymer particles of the invention comprise polyacrylamide particles with uniform size distributions having low coefficients of variations, which result in reduced particle-to-particle variation in analytical assays. Such particle compositions are used in various amplification reactions to make amplicon libraries from nucleic acid fragment libraries.
Abstract translation: 本发明提供了在核酸分析中具有应用的颗粒组合物。 本发明的核酸聚合物颗粒允许多核苷酸在其整个体积中被连接，以便比仅通过表面附着可实现的更高的负载能力。 在一个方面，本发明的核酸聚合物颗粒包含具有低变异系数的具有均匀尺寸分布的聚丙烯酰胺颗粒，这导致分析测定中粒子与粒子变化的减少。 这种颗粒组合物用于各种扩增反应以制备来自核酸片段文库的扩增子文库。
-
Patent Agency Ranking
公开(公告)号：US07960532B2
公开(公告)日：2011-06-14
申请号：US12503893
申请日：2009-07-16
Applicant: David Light , Kirk McLean
Inventor： David Light , Kirk McLean
IPC: C07H21/04
CPC classification number: G01N33/86 , A61K2039/505 , C07K16/36 , C07K16/40 , C07K2317/622 , G01N2800/224
Abstract: This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, an inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including but not limited to deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.
Abstract translation: 本发明涉及与单独的组织因子（TF）相比，与因子VIIa /组织因子（FVIIa / TF）复合物具有更高亲和力结合的新型抗体，不竞争与FVII和FX的结合，抑制FX激活。 抗体在损伤部位结合并防止血栓形成的发生。 抗体可用于治疗各种血栓形成病症，包括但不限于深静脉血栓形成，弥散性血管内凝血和急性冠状动脉综合征。
-
公开(公告)号：US20110027268A1
公开(公告)日：2011-02-03
申请号：US12744849
申请日：2008-11-19
Applicant: Antje Kahnert , David Light , Doug Schneider , Renate Parry , Noboru Satozawa , Tara Heitner , Stefan Steidl , Ulrike Schubert
Inventor： Antje Kahnert , David Light , Doug Schneider , Renate Parry , Noboru Satozawa , Tara Heitner , Stefan Steidl , Ulrike Schubert
CPC classification number: C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 4O.kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
Abstract translation: 本发明提供了重组抗原结合区和含有这样的抗原结合区的抗体和功能片段，所述抗原结合区对于多个肿瘤如胰腺和卵巢肿瘤间皮瘤中过表达的膜锚定的40kDa的间皮素多肽是特异性的 和肺癌细胞。 因此，这些抗体可用于治疗这些和其他病症和病症。 本发明的抗体也可用于诊断领域，以及进一步研究间皮素在与癌症相关疾病进展中的作用。 本发明还提供了编码前述抗体的核酸序列，含有该抗体的载体，药物组合物和具有使用说明书的试剂盒。
-
公开(公告)号：US07696439B2
公开(公告)日：2010-04-13
申请号：US11801336
申请日：2007-05-09
Applicant: David Light
Inventor： David Light
CPC classification number: H05K3/062 , H05K3/202 , H05K2201/0361 , H05K2203/0384 , Y10T29/49224
Abstract: A layered metal structure is provided in accordance with an aspect of the invention. The structure can be used, for example, to fabricate a conductive interconnect element for conductively interconnecting one or more microelectronic elements. The layered structure includes first and second metal layers each of which may include one or more of copper or aluminum, for example. An intervening layer, may include for example, chromium between the first and second metal layers, chromium being resistant to an etchant usable to pattern the first and second metal layers selectively to the intervening layer. An etchant such as cupric chloride, ferric chloride (FeCl3), a peroxysulfuric composition, or a persulfate composition may be used to pattern the first and second metal layers in such case.
Abstract translation: 根据本发明的一个方面提供了层状金属结构。 该结构可以用于例如制造导电互连一个或多个微电子元件的导电互连元件。 层状结构包括例如可以包括铜或铝中的一种或多种的第一和第二金属层。 中间层可以包括例如在第一和第二金属层之间的铬，铬耐腐蚀剂可以选择性地将第一和第二金属层图案化成中间层。 在这种情况下，可以使用诸如氯化铜，氯化铁（FeCl 3），过氧化硫组合物或过硫酸盐组合物的蚀刻剂来图案化第一和第二金属层。
-
公开(公告)号：US20090317390A1
公开(公告)日：2009-12-24
申请号：US12503893
申请日：2009-07-16
Applicant: David Light , Kirk McLean
Inventor： David Light , Kirk McLean
IPC: A61K39/395 , C07H21/04
CPC classification number: G01N33/86 , A61K2039/505 , C07K16/36 , C07K16/40 , C07K2317/622 , G01N2800/224
Abstract: This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, and inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including, but not limited to, deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome.
Abstract translation: 本发明涉及以与构成因子（FVIIa / TF）复合物相比更高的亲和力结合的单克隆抗体，不与FVII和FX竞争结合TF，并且抑制FX激活。 抗体在损伤部位结合并防止血栓形成的发生。 抗体可用于治疗各种血栓形成病症，包括但不限于深静脉血栓形成，弥散性血管内凝血和急性冠状动脉综合征。
-
公开(公告)号：US20070155726A1
公开(公告)日：2007-07-05
申请号：US11644244
申请日：2006-12-22
Applicant: Damian Arnaiz , Greg Brown , Emmanuel Claret , Arwed Cleve , David Davey , William Guilford , Seock-Kyu Khim , Thomas Kirkland , Monica Kochanny , Amy Liang , David Light , John Parkinson , David Vogel , Guo Wei , Bin Ye
Inventor： Damian Arnaiz , Greg Brown , Emmanuel Claret , Arwed Cleve , David Davey , William Guilford , Seock-Kyu Khim , Thomas Kirkland , Monica Kochanny , Amy Liang , David Light , John Parkinson , David Vogel , Guo Wei , Bin Ye
IPC: A61K31/551 , A61K31/495 , A61K31/46 , A61K31/445 , A61K31/407
CPC classification number: C07D487/08 , C07B2200/07 , C07C217/58 , C07C229/08 , C07C229/38 , C07C233/78 , C07C255/57 , C07C271/20 , C07C2601/14 , C07D207/04 , C07D207/09 , C07D207/16 , C07D211/26 , C07D211/34 , C07D211/58 , C07D243/08 , C07D263/14 , C07D263/32 , C07D277/22 , C07D277/68 , C07D295/04 , C07D295/096 , C07D295/16 , C07D401/10 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D451/02 , C07D451/04
Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.
Abstract translation: 本发明涉及式（I）化合物：其中r，q，R，R 2，R 3，R 4，R R 5，R 5b，R 5c，R 6a，R 6b，R 6b，R 6b，R 6b，R 6b， 本文描述了作为单一立体异构体或作为其中R 1，R 2，R 8和R 9的混合物 立体异构体或其药学上可接受的盐，溶剂合物，包合物，多晶型物，铵离子，N-氧化物或前药; 其是白三烯A 4水解酶抑制剂，因此可用于治疗炎症性疾病。 还公开了包含本发明化合物的药物组合物和制备本发明化合物的方法。
-
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.05 seconds)
